Claims for Patent: 11,364,224
✉ Email this page to a colleague
Summary for Patent: 11,364,224
Title: | Pharmaceutical composition for treating migraine |
Abstract: | The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base. |
Inventor(s): | Prabhakara; Prabhu (Udupi, IN), Patil; Rajesh Ramesh (Thane, IN), Gupta; Piyush (Ghaziabad, IN), Raghuvanshi; Rajeev Singh (Gurgaon, IN), Namboodiripad; Anil N. (Yardley, PA) |
Assignee: | Upsher-Smith Laboratories, LLC (Maple Grove, MN) |
Application Number: | 16/718,414 |
Patent Claims: |
1. A method of treating acute migraine in a patient, the method comprising: subcutaneously administering by autoinjector a composition to the patient, the composition
comprising an aqueous solution comprising 4.2 mg sumatriptan succinate and sodium chloride in a range of 4.15 mg to 4.2 mg in a total volume of 0.5 mL; wherein the composition has osmolality between 275 to 315 mOsm/kg; and wherein the administration of
the compositions results in a system exposure in the patient characterized by at least one of the following plasma profiles: C.sub.max of about 35 ng/mL to about 57 ng/mL; AUC.sub.0-2 of about 30 nghr/mL to about 50 nghr/mL; and AUC.sub.0-inf of about
43 nghr/mL to about 70 nghr/mL.
2. The method of claim 1, wherein the composition has a pH of about 4.2 to 5.3. 3. The method of claim 1, wherein the patient is suffering from acute migraine. 4. The method of claim 3, wherein the patient is suffering from acute migraine with aura. 5. The method of claim 3, wherein the patient is suffering from acute migraine without aura. 6. The method of claim 1, wherein the autoinjector comprises a 0.5 mL prefilled, ready-to-use, single dose, disposable auto-injector. 7. The method of claim 1, wherein the maximum recommended frequency of administration is not more than four times a day. 8. A method of treating acute migraine in a patient, the method comprising: subcutaneously injecting a composition to the patient, the composition comprising an aqueous solution comprising 4.2 mg sumatriptan succinate and sodium chloride a range of 4.15 mg to 4.2 mg in a total volume of 0.5 mL; wherein the composition has osmolality between 275 to 315 mOsm/kg; and wherein the injection results in a system exposure in the patient characterized by at least one of the following plasma profiles: C.sub.max of about 35 ng/mL to about 57 ng/mL; AUC.sub.0-2 of about 30 nghr/mL to about 50 nghr/mL; and AUC.sub.0-inf of about 43 nghr/mL to about 70 nghr/mL. 9. The method of claim 8, wherein the composition has a pH of about 4.2 to 5.3. 10. The method of claim 8, wherein the patient is suffering from acute migraine. 11. The method of claim 10, wherein the patient is suffering from acute migraine with aura. 12. The method of claim 10, wherein the patient is suffering from acute migraine without aura. 13. The method of claim 8, wherein the method comprises injecting the composition using an autoinjector. 14. The method of claim 13, wherein the autoinjector comprises a 0.5 mL prefilled, ready-to-use, single dose, disposable auto-injector. 15. The method of claim 8, wherein the maximum recommended frequency of administration is not more than four times a day. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.